EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription ( JAK / STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment‐related pathways

Trinayan Kashyap iD, Andrea A Ellero, Christopher J Walker, Marie E Maloof, Min Lu, Lijuan Xia, Ronald Hoffman, Pietro Taverna

British Journal of Haematology · 2026

DOI: 10.1111/bjh.70639 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Trinayan Kashyap und 7 weiteren Autor:innen. Beteiligte Einrichtung: Karyopharm Therapeutics, Newton, Massachusetts, USA. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Pyrazoles, Signal Transduction, Janus Kinase 2. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by splenomegaly, constitutional symptoms, marrow fibrosis, cytopenias and inflammation. Janus kinase 2 (JAK2) inhibitors, such as ruxolitinib, reduce splenomegaly and alleviate symptoms but have limited disease‐modifying activity, and resistance frequently develops. Selinexor, an oral selective exportin (XPO1) inhibitor, restores nuclear retention of tumour suppressors and inhibitors of inflammatory signalling. Dual XPO1/JAK2 inhibition targets complementary downstream pathways, enhancing suppression of MF progenitor cell fitness. We evaluated selinexor plus ruxolitinib in MF models, including JAK2 V617F or calreticulin ( CALR ) exon 9‐mutant MPN cell lines and samples from patients with MF. The combination showed greater anti‐proliferative activity than JAK2 inhibition alone and suppressed colony formation from MF Cluster of Differentiation 34 (CD34)+ cells. Selinexor remained active in a ruxolitinib‐resistant MPN cell line, inducing G1 arrest and apoptosis. Multi‐omic analyses demonstrated increased nuclear retention of p53 and disruption of Nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐κB) and Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling, complementing and extending ruxolitinib‐targeted pathways. The combination suppressed NF‐κB transcriptional activity and reduced Tumor Necrosis Factor alpha (TNFα), Interleukin‐6 (IL‐6) and Monocyte Chemoattractant Protein‐1 (MCP‐1) secretion from MF patient peripheral blood mononuclear cells. These findings highlight that selinexor plus ruxolitinib affects both MF haematopoietic cell–intrinsic and microenvironment‐related pathways, providing a novel disease‐modifying strategy with the potential to improve clinical outcomes in patients with MF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary MyelofibrosisPyrazolesSignal TransductionJanus Kinase 2HydrazinesSTAT Transcription FactorsJanus KinasesHumansNitrilesPyrimidinesActive Transport, Cell NucleusExportin 1 ProteinKaryopherinsTriazolesReceptors, Cytoplasmic and NuclearCell Line, TumorTumor MicroenvironmentCalreticulinJanus Kinase Inhibitors

Stichwörter der Autor:innen

JAK/STATNF‐κBexportin 1myelofibrosisp53ruxolitinibselinexor

Substanzen

NitrilesPyrazolesruxolitinibJanus Kinase 2PyrimidinesHydrazinesExportin 1 ProteinJAK2 protein, humanselinexorKaryopherins

Autor:innen und Institutionen

  • Karyopharm Therapeutics, Newton, Massachusetts, USA.
  • Division of Hematology/Oncology Section, Tisch Cancer Institute and Department of Medicine, Myeloproliferative Neoplasm-Research Consortium, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

ORCID-Profile: Trinayan Kashyap

Zitieren

APA

Kashyap, T., Ellero, A. A., Walker, C. J., Maloof, M. E., Lu, M., Xia, L., Hoffman, R., & Taverna, P. (2026). Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription ( JAK / STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment‐related pathways. British Journal of Haematology. https://doi.org/10.1111/bjh.70639

Vancouver

Kashyap T, Ellero AA, Walker CJ, Maloof ME, Lu M, Xia L, et al. Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription ( JAK / STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment‐related pathways. British Journal of Haematology. 2026. doi:10.1111/bjh.70639

BibTeX
@article{Kashyap2026,
  author = {Kashyap, Trinayan and Ellero, Andrea A and Walker, Christopher J and Maloof, Marie E and Lu, Min and Xia, Lijuan and Hoffman, Ronald and Taverna, Pietro},
  title = {Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription ( JAK / STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment‐related pathways},
  journal = {British Journal of Haematology},
  year = {2026},
  doi = {10.1111/bjh.70639}
}
Kostenlos starten →